<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931539</url>
  </required_header>
  <id_info>
    <org_study_id>SHP620-303</org_study_id>
    <secondary_id>2015-004725-13</secondary_id>
    <nct_id>NCT02931539</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an investigational treatment (Maribavir) is safe
      and effective in treating transplant recipient subjects with cytomegalovirus (CMV) infections
      that are refractory or resistant to treatment with ganciclovir, valganciclovir, foscarnet, or
      cidofovir.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare the Efficacy of Maribavir to Investigator-assigned Anti-CMV Therapy in CMV Viremia Clearance at the End of Study Week 8, in Transplant Recipients Who are Refractory or Resistant to Prior Anti-CMV Treatment</measure>
    <time_frame>Week 8</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification less than (&lt;) LLOQ; that is (i.e), &lt;137 International Units per millilitre (IU/mL) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days, regardless of whether either study assigned treatment will be discontinued before the end of the stipulated 8 weeks of therapy. The difference in proportion of subjects with confirmed CMV viremia clearance, at the end of Study Week 8, between treatment groups (maribavir and investigator's choice of anti CMV treatment) will be obtained using Cochran-Mantel-Haenszel (CMH) weighted average across all strata, and analyzed using CMH test with transplant type and baseline plasma CMV DNA concentration as 2 stratification factors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Compare the Efficacy of Two Study Treatment Arms on CMV Viremia Clearance and Tissue-invasive CMV Disease Improvement or Resolution at the End of Week 8, and Week 16</measure>
    <time_frame>Week 8, Week 16</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (&lt;LLOQ; i.e &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days. Tissue invasive CMV disease will be defined as described by Ljungman et al. (2002 and 2016). The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues or identification of CMV in biopsy tissue samples. Achievement of CMV viremia clearance and resolution or improvement of tissue-invasive CMV disease for subjects symptomatic at baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease for subjects asymptomatic at baseline at the end of Study Week 8, followed by maintenance of this treatment effect (Follow-up Week 16).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Efficacy of Maribavir to Investigator-assigned Anti-CMV Therapy on CMV Viremia Clearance After Completion of 8 Weeks of Study Treatment in Transplant Recipients Who are Refractory or Resistant to Prior Anti-CMV Treatment</measure>
    <time_frame>Week 8</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (&lt;LLOQ; i.e &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Efficacy of Two Study Treatment Arms on CMV Viremia Clearance and Tissue-Invasive CMV Disease Improvement or Resolution after Completion of 8 Weeks Through Weeks 12, 16 and 20</measure>
    <time_frame>Week 8, Week 12, Week 16, Week 20</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (&lt;LLOQ; i.e &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days. Tissue invasive CMV disease will be defined as described by Ljungman et al. (2002 and 2016). The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues OR identification of CMV in biopsy tissue samples. The achievement of the confirmed CMV viremia clearance and resolution or improvement of tissue invasive CMV disease for subjects symptomatic at baseline or achievement of clearance of viremia and no symptoms of tissue invasive CMV disease for subjects asymptomatic at baseline after receiving 8 weeks of study-assigned treatment, followed by maintenance of this treatment effect through study weeks 12, week 16 and week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Two Study Treatment for Maintenance of CMV Viremia Clearance and Resolution or Improvement of Tissue Invasive CMV Disease</measure>
    <time_frame>Week 8, Week 12, Week 20</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (&lt;LLOQ; i.e &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days. Tissue invasive CMV disease will be defined as described by Ljungman et al. (2002 and 2016). The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues OR identification of CMV in biopsy tissue samples. Maintenance of CMV viremia clearance and resolution or improvement of tissue invasive CMV disease will be analyzed at Weeks 8, 12 and 20 post-treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Incidence of Recurrence of CMV Viremia in Two Study Treatment Arms During the Study</measure>
    <time_frame>Throughout 8 Weeks to 12 Weeks</time_frame>
    <description>Recurrence of CMV viremia is defined as the presence of signs or symptoms of the tissue invasive CMV disease (same or new symptomatology) confirmed as per Ljungman et al. (2016), after the period of resolution of the disease in subjects symptomatic at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With incidence of Recurrence of CMV Viremia in Two Study Treatment Arms When Subjects are On Treatment and Off Treatment</measure>
    <time_frame>Week 8 to Week 20</time_frame>
    <description>Recurrence of CMV viremia is defined as the presence of signs or symptoms of the tissue invasive CMV disease (same or new symptomatology) confirmed as per Ljungman et al. (2016), after the period of resolution of the disease in subjects symptomatic at baseline. Incidence of recurrence of CMV viremia is evaluated in the two study treatment arms when subjects are on and off treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Mutations in the CMV Genes Conferring Resistance to Maribavir</measure>
    <time_frame>Week 0 to week 20</time_frame>
    <description>Specific mutations in the UL97 and/or UL54 human cytomegalovirus (HCMV) genes are associated with resistance to certain anti-CMV drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With All-cause Mortality</measure>
    <time_frame>Week 0 to week 20</time_frame>
    <description>Mortality will be assessed by the number of subjects who died between week 0 to week 20. A summary of death details will be given which include whether the subject died between week 0 to week 20, whether the death is related sepsis, cause of death, the source of the information, and whether the cause of death will be verified by a death record. Number of subjects who died at the end of the study and the corresponding 95% confidence intervals (CIs) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the Efficacy of Maribavir Administered as the Rescue Treatment on CMV Viremia Clearance as Measured by Plasma CMV DNA Concentration, at the End of the Study Treatment Period</measure>
    <time_frame>Throughout 8 weeks from the entry into maribavir rescue arm</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (&lt;LLOQ; i.e &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV Viremia Clearance, Resolution/Improvement of Tissue Invasive CMV Disease if Present at Baseline and no New Onset of Disease in Subjects Asymptomatic at Baseline, at the End of the Study Treatment and the Follow up in Maribavir Rescue Arm</measure>
    <time_frame>Throughout 8 weeks from the entry into maribavir rescue arm to 8 weeks of follow-up</time_frame>
    <description>Viremia clearance will be defined as plasma CMV DNA concentration below the lower limit of quantification (&lt;LLOQ; i.e &lt;137 IU/mL when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test at a central speciality laboratory, in 2 consecutive postbaseline samples, separated by at least 5 days. Tissue invasive CMV disease will be defined as described by Ljungman et al. (2002 and 2016). The gold standard for diagnosing CMV tissue invasive disease is the identification of CMV inclusions in the infected cells of the tissues OR identification of CMV in biopsy tissue samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Overall Study Adverse Events (AEs), Overall Study Serious Adverse Events (SAEs), and Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)</measure>
    <time_frame>Week 0 to Week 20</time_frame>
    <description>An AE is any untoward medical occurrence in a subject who will receive study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as AEs observed during the on treatment observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Maribavir Based on Sparse Sampling as Measured by Area Under The Curve (AUC)</measure>
    <time_frame>Week 1 to week 8</time_frame>
    <description>Maribavir PK will be analyzed for all subjects with maribavir plasma concentration results. The AUC reflects the actual body exposure to drug after administration of a dose of the drug.This area under the curve is dependant on the rate of elimination of the drug from the body and the dose administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Laboratory Tests</measure>
    <time_frame>Week 0 to week 20</time_frame>
    <description>Clinical laboratory tests include hematology, chemistry, urinalysis, HBV, HCV, pregnancy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">351</enrollment>
  <condition>Cytomegalovirus (CMV)</condition>
  <arm_group>
    <arm_group_label>Maribavir Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 200 mg tablets will be taken by mouth twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anti-CMV agent best suited to treat the respective subject. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maribavir</intervention_name>
    <description>Maribavir 2*200 mg two times per day</description>
    <arm_group_label>Maribavir Treatment</arm_group_label>
    <other_name>SHP620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Investigator-Assigned Treatment</intervention_name>
    <description>Active Comparator: anti-CMV agent</description>
    <arm_group_label>Investigator-Assigned Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject must be able to provide written, personally signed, and dated informed
             consent to participate in the study before completing any study-related procedures. As
             applicable, a parent/both parents or legally authorized representative (LAR) must
             provide signature of informed consent and there must be documentation of assent by the
             subject before completing any study-related procedures.

          2. The subject must be a recipient of hematopoietic stem cell or solid organ transplant.

          3. The subject must have a documented CMV infection in whole blood or plasma, with a
             screening value of greater than or equal to (&gt;=) 2730 international units per
             milliliter (IU/mL) in whole blood or &gt;= 910 IU/mL in plasma in 2 consecutive
             assessments, separated by at least 1 day, as determined by local or central speciality
             laboratory quantitative polymerase chain reaction (qPCR) or comparable quantitative
             CMV DNA results. Both samples should be taken within 14 days prior to randomization
             with second sample obtained within 5 days prior to randomization. The same laboratory
             and same sample type (whole blood or plasma) must be used for these assessments.

          4. The subject must have a current CMV infection refractory or resistant to treatment.
             Refractory is defined as documented failure to achieve greater than (&gt;) 1 log10
             (common logarithm to base 10) decrease in CMV DNA level in whole blood or plasma after
             2 or more weeks of continuous treatment with intravenous (IV) ganciclovir, oral
             valganciclovir, IV foscarnet, or IV cidofovir. This definition applies to the current
             CMV infection and the most recently administered anti-CMV agent. Resistant is defined
             as documented failure to achieve &gt; 1 log10 (common logarithm to base 10) decrease in
             CMV DNA level in whole blood or plasma after 2 or more weeks of continuous treatment
             with IV ganciclovir, oral valganciclovir, IV foscarnet, or IV cidofovir. This
             definition applies to the current CMV infection and the most recently administered
             anti-CMV agent. AND Documentation of 1 or more CMV genetic mutations associated with
             resistance to ganciclovir, valganciclovir, foscarnet, or cidofovir.

          5. The Investigator must be willing to treat the subject with at least one of the
             available anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, or cidofovir). Note:
             Combination therapy with foscarnet and cidofovir is not permitted in the
             investigator-assigned anti-CMV treatment (IAT) arm due to the potential for serious
             nephrotoxicity.

          6. The subject must be &gt;= 12 years of age at the time of consent

          7. The subject must weigh &gt;= 35 kilogram (kg).

          8. The subject must have all of the following results as part of screening laboratory
             assessments (results from either the central laboratory or a local laboratory can be
             used for qualification):

               1. Absolute neutrophil count (ANC) &gt;= 1000/ millimeter cube (mm^3) (1.0 x
                  109^9/liter [L])

               2. Platelet count &gt;= 25,000/mm^3 [25 x 10^9/L],

               3. Hemoglobin &gt;= 8 gram per deciliter (g/dL).

               4. Estimated glomerular filtration rate (eGFR) &gt; 30 (milliliter per minute (mL/min)
                  /1.73 square meter (m^2) as assessed by Modification of Diet in Renal Disease
                  (MDRD) formula for subjects &gt;= 18 years of age or Schwartz formula for subjects
                  less than (&lt;) 18 years of age.

          9. The subject must have a negative serum beta-human chorionic gonadotropin (beta-HCG)
             pregnancy test at screening, if a female of child bearing potential. Additional urine
             pregnancy tests may be done per institutional requirements. Sexually active females of
             child bearing potential must agree to comply with any applicable contraceptive
             requirements of the protocol. If male, must agree to use an acceptable method of birth
             control, as defined in the protocol, during the study treatment administration period
             and for 90 days afterward if treated with maribavir, ganciclovir, valganciclovir, or
             cidofovir and for 180 days afterward if treated with foscarnet.

         10. The subject must be able to swallow tablets, or receive tablets crushed and/or
             dispensed in water via nasogastric or orogastric tube.

         11. The subject must be willing and have an understanding and ability to fully comply with
             study procedures and restrictions defined in the protocol.

         12. The subject must be willing to provide necessary samples (example [e.g,] biopsy) for
             the diagnosis of tissue invasive CMV disease at baseline as determined by the
             Investigator.

         13. The subject must have a life expectancy of &gt;= 8 weeks.

        Exclusion Criteria:

          1. Have a current CMV infection that is considered refractory or resistant due to
             inadequate adherence to prior anti-CMV treatment, to the best knowledge of the
             Investigator.

          2. Require ganciclovir, valganciclovir, foscarnet, or cidofovir administration for
             conditions other than CMV when study treatment is initiated (example: herpes simplex
             virus (HSV) coinfection requiring use of any of these agents after the randomization)
             or would need a coadministration with maribavir for CMV infection. NOTE: A subject who
             is not continuing with the same anti-CMV drug(s) (ganciclovir, valganciclovir or
             foscarnet) for the study treatment (if randomized to the investigator assigned
             anti-CMV treatment arm), must discontinue their use before the first dose of study
             drug. If subject is currently being treated with cidofovir and is assigned another
             anti-CMV therapy by the investigator, the subject must discontinue its use at least 14
             days prior to randomization at Visit 2/Day 0 and the first dose of study treatment.

          3. Be receiving leflunomide, letermovir, or artesunate when study treatment is initiated.
             NOTE: Subjects who may be receiving leflunomide or letermovir must discontinue the use
             at least 14 days prior to randomization at Visit 2/Day 0 and the first dose of study
             treatment. Subjects receiving artesunate must discontinue the use prior to the first
             dose of study treatment.

          4. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24
             hours prior to the first dose of study treatment that would preclude administration of
             oral/enteral medication.

          5. Have known hypersensitivity to the active substance or to an excipient for a study
             treatment.

          6. Have tissue invasive CMV disease with central nervous system involvement including the
             retina (example, CMV retinitis).

          7. Have serum aspartate aminotransferase (AST) &gt; 5 times upper limit of normal (ULN) at
             screening, or serum alanine aminotransferase (ALT) &gt; 5 times ULN at screening, or
             total bilirubin &gt;= 3.0 x ULN at screening (except for documented Gilbert's syndrome),
             by local or central lab. Subjects with biopsy confirmed CMV hepatitis will not be
             excluded from study participation despite AST or ALT &gt; 5 times ULN at screening.

          8. Have known (previously documented) positive results for human immunodeficiency virus
             (HIV).

          9. Require mechanical ventilation or vasopressors for hemodynamic support at the time of
             enrollment.

         10. Be female and pregnant or breast feeding.

         11. Have previously received maribavir.

         12. Have received any investigational agent with known anti-CMV activity within 30 days
             before initiation of study treatment or investigational CMV vaccine at any time.

         13. Have received any unapproved agent or device within 30 days before initiation of study
             treatment.

         14. Have active malignancy with the exception of nonmelanoma skin cancer. Subjects who
             have had a hematopoietic stem cell transplant (HSCT) and who experience relapse or
             progression of the malignancy as per investigator's opinion are not to be enrolled.

         15. Be undergoing treatment for acute or chronic hepatitis C.

         16. Have any clinically significant medical or surgical condition that, in the
             investigator's opinion, could interfere with the interpretation of study results,
             contraindicate the administration of the assigned study treatment, or compromise the
             safety or well-being of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>866-842-5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Baddley, MD, MSPH</last_name>
      <phone>205-934-5191</phone>
      <email>jbaddley@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>John Baddley, MD, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjeet Dadwal, MD</last_name>
      <phone>626-256-4673</phone>
      <email>sdadwal@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sanjeet Dadwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Blodget, MD</last_name>
      <phone>323-409-4398</phone>
      <email>eblodget@usc.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Blodget, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Winston, MD</last_name>
      <phone>310-825-9264</phone>
      <email>dwinston@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Drew Winston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maricar Malinis, MD</last_name>
      <phone>203-785-3561</phone>
      <email>maricar.malinis@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Maricar Malinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Transplant Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Nibhanupudy, MD</last_name>
      <phone>407-303-2474</phone>
      <email>bobby.nibhanupudy.md@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Bobby Nibhanupudy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Lyon III, MD</last_name>
      <phone>404-712-2051</phone>
      <email>gmlyon@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Lyon III, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Mullane, DO, PharmD</last_name>
      <phone>773-702-3756</phone>
      <email>kmullane@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Mullane, DO, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ison, MD</last_name>
      <phone>312-695-4186</phone>
      <email>mgison@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Ison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Clark, MD</last_name>
      <phone>708-216-3135</phone>
      <email>nmclark@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Gedaly, MD</last_name>
      <phone>859-323-4661</phone>
      <email>roberto.gedaly@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Roberto Gedaly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Garcia-Diaz</last_name>
      <phone>504-842-5748</phone>
      <email>jgarcia-diaz@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Julia Garcia-Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdolreza Haririan</last_name>
      <phone>410-328-5720</phone>
      <email>ahariria@som.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Abdolreza Haririan, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Avery, MD</last_name>
      <phone>443-287-4694</phone>
      <email>ravery4@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Robin Avery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Wojciechowski</last_name>
      <phone>617-724-9673</phone>
      <email>dwojciechowski@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Wojciechowski, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Marty</last_name>
      <phone>617-732-8881</phone>
      <email>fmarty@partners.org</email>
    </contact>
    <investigator>
      <last_name>Francisco Marty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Gibson</last_name>
      <phone>508-856-1978</phone>
      <email>laura.gibson@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Gibson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Kaul, MD</last_name>
      <phone>734-936-5205</phone>
      <email>kauld@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Kaul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Alangaden</last_name>
      <phone>313-916-2573</phone>
      <email>galanga1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>George Alangaden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dilip Samarapungavan, MD</last_name>
      <phone>248-551-2594</phone>
      <email>dilip.samarapungavan@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>Dilip Samarapungavan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo-Anne Young</last_name>
      <phone>612-625-8642</phone>
      <email>vanbu004@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>59905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymund Razonable</last_name>
      <phone>507-284-3747</phone>
      <email>razonable.raymund@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Raymund Razonable</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Florescu, MD</last_name>
      <phone>402-559-8930</phone>
    </contact>
    <investigator>
      <last_name>Diana Florescu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Pereira</last_name>
      <phone>212-305-7185</phone>
      <email>mp2323@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Marcus Pereira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genovefa Papnicolaou, MD</last_name>
      <phone>212-639-8361</phone>
      <email>papanicg@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Genovefa Papanicolaou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Small, MD</last_name>
      <phone>914-493-8244</phone>
      <email>cbs9003@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Catherine Small, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Alexander</last_name>
      <phone>919-668-0789</phone>
      <email>barbara.alexander@dm.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara Alexander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Ardura</last_name>
      <phone>614-722-4452</phone>
      <email>monica.ardura@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Monica Ardura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Blumberg, MD</last_name>
      <phone>215-662-7066</phone>
      <email>blumbere@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Emily Blumberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Silveira</last_name>
      <phone>412-647-0996</phone>
      <email>silveirafd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Fernanda Silveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinayak Rohan</last_name>
      <phone>843-792-4003</phone>
      <email>rohanv@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Vinayak Rohan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashok Srinivasan, BS, MB, MD</last_name>
      <phone>901-595-4720</phone>
      <email>Ashok.Srinivasan@STJUDE.ORG</email>
    </contact>
    <investigator>
      <last_name>Ashok Srinivasan, BS, MB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo La Hoz, MD</last_name>
      <phone>214-645-2800</phone>
      <email>ricardo.lahoz@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo La Hoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Fischbach</last_name>
      <phone>817-922-7667</phone>
      <email>fischbachb@dneph.com</email>
    </contact>
    <investigator>
      <last_name>Bernard Fischbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Cotton, MD</last_name>
      <phone>832-355-1400</phone>
      <email>ronaldc@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Cotton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Chemaly, MD</last_name>
      <phone>713-792-5381</phone>
      <email>rfchemaly@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Roy Chemaly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuad Shihab</last_name>
      <phone>801-585-3823</phone>
      <email>fuad.shihab@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Fuad Shihab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Hill, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joshua Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip O'Connell</last_name>
      <phone>+61298456848</phone>
      <email>philip.oconnell@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Philip O'Connell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James McMahon</last_name>
      <phone>+61390766908</phone>
      <email>ja.mcmahon@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>James McMahon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Sasadeusz</last_name>
      <phone>+61393428616</phone>
      <email>joe.sasadeusz@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Joe Sasadeusz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Washington</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerry MacQuillan, BSc, MBBS, MD, PhD</last_name>
      <phone>+61864573228</phone>
      <email>gerry.macquillan@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Gerry MacQuillan, BSc, MBBS, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Campbell</last_name>
      <phone>+61731765080</phone>
      <email>Scott.Campbell@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Scott Campbell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tiroler Landeskrankenanstalten GmbH</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Schneeberger, MD</last_name>
      <phone>+4351250480339</phone>
      <email>stefan.schneeberger@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Stefan Schneeberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>26500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Gadisseur</last_name>
      <phone>+3238213250</phone>
      <email>alain.gadisseur@uza.be</email>
    </contact>
    <investigator>
      <last_name>Alain Gadisseur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Kuypers</last_name>
      <phone>+3216344580</phone>
      <email>dirk.kuypers@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Dirk Kuypers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens</last_name>
      <phone>+3216346880</phone>
      <email>johan.maertens@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Johan Maertens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan AV</name>
      <address>
        <city>Brugge</city>
        <state>West-Vlaanderen</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Selleslag</last_name>
      <phone>+3250453061</phone>
      <email>dominik.selleslag@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Dominik Selleslag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Zachée</last_name>
      <phone>+3232177418</phone>
      <email>pierre.zachee@zna.be</email>
    </contact>
    <investigator>
      <last_name>Pierre Zachée</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri Schots</last_name>
      <phone>+3224776040</phone>
      <email>rik.schots@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Henri Schots</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickaël Aoun, MD</last_name>
      <phone>+3225413706</phone>
      <email>michael.aoun@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Mickaël Aoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>10700</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique Jacobs</last_name>
      <phone>+3225554708</phone>
      <email>frederique.jacobs@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Frédérique Jacobs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tessa Kerre, MD</last_name>
      <phone>+3293326654</phone>
      <email>tessa.kerre@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Tesse Kerre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Cervera, MD</last_name>
      <phone>(780) 492-8085</phone>
      <email>cerveraa@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Carlos Cervera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shariq Haider, MD</last_name>
      <phone>(905) 521-2100</phone>
      <email>haider@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Shariq Haider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santhosh Thyagu, MD</last_name>
      <phone>(416) 946-4501</phone>
      <phone_ext>5706</phone_ext>
      <email>santhosh.thyagu@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Santhosh Thyagu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Vinh, MD</last_name>
      <phone>(514) 934-1934</phone>
      <email>donald.vinh@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Donald Vinh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Radovan Vrhovac</last_name>
      <phone>+38512388644</phone>
    </contact>
    <investigator>
      <last_name>Radovan Vrhovac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest - Hospital Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <state>Finistère</state>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick Le Meur</last_name>
      <phone>+33298347074</phone>
      <email>yannick.lemeur@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Yannick Le Meur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Rangueil</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nassim Kamar</last_name>
      <phone>+33561323283</phone>
      <email>kamar.n@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Nassim Kamar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <state>Hauts-de-Seine</state>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Roux</last_name>
      <phone>+33688084754</phone>
      <email>a.roux@hopital-foch.org</email>
    </contact>
    <investigator>
      <last_name>Antoine Roux</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Rennes</name>
      <address>
        <city>Rennes</city>
        <state>Ille-et-Vilaine</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu Revest</last_name>
      <phone>+33299289564</phone>
      <email>matthieu.revest@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Matthieu Revest</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau</name>
      <address>
        <city>Tours</city>
        <state>Indre-et-Loire</state>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Buchler</last_name>
      <phone>+33247473746</phone>
      <email>buchler@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Matthias Buchler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nantes</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice Chevallier</last_name>
      <phone>+33240083994</phone>
      <email>patrice.chevallier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Zoulim</last_name>
      <phone>+33426732733</phone>
      <email>fabien.zoulim@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Fabien Zoulim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-bénite</city>
        <state>Rhône</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Ducastelle-Lepretre</last_name>
      <phone>+33478862237</phone>
      <email>sophie.ducastelle-lepretre@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Ducastelle-Lepretre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Choukroun</last_name>
      <phone>+33322456000</phone>
      <email>choukroun.gabriel@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel Choukroun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <state>Val-de-Marne</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Cordonnier</last_name>
      <phone>+33149812057</phone>
      <email>catherine.cordonnier@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine Cordonnier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faouzi Saliba</last_name>
      <phone>+331455964124094</phone>
      <email>faouzi.saliba@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Faouzi Saliba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Hôpital Sud</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berengere Gruson</last_name>
      <phone>+33322455914</phone>
      <email>gruson.berengere@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Berengere Gruson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Elizabeth Heng</last_name>
      <phone>+33473751425</phone>
      <email>aheng@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Elizabeth Heng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de GRENOBLE</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Epaulard, MD</last_name>
      <phone>+33476765291</phone>
      <email>oepaulard@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Epaulard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine Faure</last_name>
      <phone>+33320445962</phone>
      <email>karine.faure@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Karine Faure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Alain</last_name>
      <phone>+33555056728</phone>
      <email>Sophie.Alain@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Alain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupement Hospitalier Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Morelon</last_name>
      <phone>+33472110150</phone>
      <email>emmanuel.morelon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Morelon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Frange</last_name>
      <phone>+33144494961</phone>
      <email>pierre.frange@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Frange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Socie</last_name>
      <phone>+33142499824</phone>
      <email>gerard.socie@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gerard Socie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Mohty</last_name>
      <phone>+33149282000</phone>
      <email>mohamad.mohty@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Mohamad Mohty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Poitiers La Miletrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Thierry</last_name>
      <phone>+33549444444</phone>
      <email>antoine.thierry@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Thierry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de la Loire</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerome Cornillon, PhD</last_name>
      <phone>+33477917060</phone>
      <email>jerome.cornillon@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Jerome Cornillon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Civil</name>
      <address>
        <city>STRASBOURG Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Caillard-Ohlmann</last_name>
      <phone>+33369551320</phone>
      <email>sophie.caillard@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Caillard-Ohlmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Lioure</last_name>
      <phone>+33388116728</phone>
      <email>bruno.lioure@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Bruno Lioure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wiesener, MD</last_name>
      <phone>+4991318536353</phone>
      <email>michael.wiesener@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Michael Wiesener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Werner Heinz, MD</last_name>
      <phone>+4993120136611</phone>
      <email>heinz_w@medizin.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Werner Heinz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Witzke, MD</last_name>
      <phone>+492017233955</phone>
      <email>oliver.witzke@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Witzke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Wagner, MD</last_name>
      <phone>+4968411623154</phone>
      <email>eva.wagner@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Eva Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, MD</last_name>
      <phone>+493419713050</phone>
      <email>dietger.niederwieser@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dietger Niederwieser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Winkler, MD</last_name>
      <phone>+4991318543112</phone>
      <email>julia.winkler@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Julia Winkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Bethge, MD</last_name>
      <phone>+4970712982711</phone>
      <email>wolfgang.bethge@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele S.r.l. - PPDS</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Secchi, MD</last_name>
      <phone>+390226432805</phone>
      <email>secchi.antonio@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Secchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Tarella, MD</last_name>
      <phone>+390257489538</phone>
      <email>corrado.tarella@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Corrado Tarella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona-Umberto I G.M. Lancisi G. Salesi</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Olivieri, MD</last_name>
      <phone>+390715964226</phone>
      <email>a.olivieri@univpm.it</email>
    </contact>
    <investigator>
      <last_name>Attilio Olivieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Aversa, MD</last_name>
      <phone>+390521903263</phone>
      <email>franco.aversa@unipr.it</email>
    </contact>
    <investigator>
      <last_name>Franco Aversa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56216</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Petrini, MD</last_name>
      <phone>+39050993488</phone>
      <email>mario.petrini@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Mario Petrini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Citterio, MD</last_name>
      <phone>+390630154437</phone>
      <email>franco.Citterio@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Franco Citterio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>12345</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elda Righi, MD</last_name>
      <phone>+390432559355</phone>
      <email>elda.righi@libero.it</email>
    </contact>
    <investigator>
      <last_name>Elda Righi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital (SGH)</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aloysius Ho, MD</last_name>
      <phone>+6563214722</phone>
      <email>aloysius.ho.y@singhealth.com.sg</email>
    </contact>
    <investigator>
      <last_name>Aloysius Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Ferra Coll, MD</last_name>
      <phone>+34934978987</phone>
      <email>cferra@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Christelle Ferra Coll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Miguel Montejo Baranda</last_name>
      <phone>+34946006000x2330</phone>
      <email>josemiguel.montejobaranda@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>José Miguel Montejo Baranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacio Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Guirado Perich</last_name>
      <phone>+34934169700</phone>
      <email>lguirado@fundacio-puigvert.es</email>
    </contact>
    <investigator>
      <last_name>Luis Guirado Perich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Len, MD</last_name>
      <email>oscar.len@vhir.org</email>
    </contact>
    <investigator>
      <last_name>Oscar Len, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Garcia Cadenas, MD</last_name>
      <phone>+34935537142</phone>
      <email>igarciaca@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Irene Garcia Cadenas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oriol Bestard Matamoros, MD</last_name>
      <phone>+34932607614</phone>
      <email>obestard@bellvitgehospital.cat</email>
    </contact>
    <investigator>
      <last_name>Oriol Bestard Matamoros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Duarte Palomino, MD</last_name>
      <phone>+34911917809</phone>
      <email>rduarte.work@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Duarte Palomino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Lourdes Vazquez Lopez, MD</last_name>
      <phone>+34923291100</phone>
      <phone_ext>55974</phone_ext>
      <email>lvazlo@usal.es</email>
    </contact>
    <investigator>
      <last_name>Maria Lourdes Vazquez Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Solano, Sr., MD, PhD</last_name>
      <phone>+34963862625</phone>
      <email>solano_car@gva.es</email>
    </contact>
    <investigator>
      <last_name>Carlos Solano, Sr., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Aguilera Sancho-Tello, MD</last_name>
      <phone>+34963862700</phone>
      <email>toyagui@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Aguilera Sancho-Tello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Sanz Caballer, MD</last_name>
      <phone>+34961245876</phone>
      <email>sanz_jai@gva.es</email>
    </contact>
    <investigator>
      <last_name>Jaime Sanz Caballer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <state>Birmingham</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nithya Krishnan</last_name>
      <phone>+442476968296</phone>
      <email>nithya.krishnan@uhcw.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nithya Krishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>West Midlands</city>
        <state>Birmingham</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhuvan Kishore</last_name>
      <phone>+441214243699</phone>
      <email>bhuvan.kishore@heartofengland.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Bhuvan Kishore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre - PPDS</name>
      <address>
        <city>Glasgow</city>
        <state>Glasgow City</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Grant McQuaker</last_name>
      <phone>+4401413017694</phone>
      <email>Grant.McQuaker@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Ian Grant McQuaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>Hampstead</city>
        <state>London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Harber, MBBS, PhD</last_name>
      <phone>+02077940500</phone>
      <email>mark.harber@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Mark Harber, MBBS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ Hosp of South Manchester NHS Foundation Trust</name>
      <address>
        <city>Wythenshawe</city>
        <state>Manchester</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizar Yonan, MB</last_name>
      <phone>+441612912092</phone>
      <email>nizar.yonan@uhsm.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nizar Yonan, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Childrens Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Yorkshire</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Patrick</last_name>
    </contact>
    <investigator>
      <last_name>Katharine Patrick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospitals NHS Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdelkader Hammad</last_name>
      <phone>+441517062390</phone>
      <email>abdul.hammad@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Abdelkader Hammad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizam Mamode, MB</last_name>
      <phone>+442071888476</phone>
      <email>nizam.mamode@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nizam Mamode, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aileen Marshall, PhD</last_name>
      <phone>+442077940500</phone>
      <email>aileen.marshall@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Aileen Marshall, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dragana Milojkovic</last_name>
      <phone>+442033135038</phone>
    </contact>
    <investigator>
      <last_name>Dragana Milojkovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Van Dellen, MD</last_name>
      <phone>+01612763647</phone>
      <email>david.vandellen@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>David Van Dellen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Mason</last_name>
      <phone>+441865225802</phone>
      <email>phil.mason@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Philip Mason</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Cidofovir</mesh_term>
    <mesh_term>Foscarnet</mesh_term>
    <mesh_term>Phosphonoacetic Acid</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

